Crescendo Biologics is a biopharmaceutical company discovering and developing potent, highly differentiated Humabody® therapeutics in Oncology.
Humabody therapeutics are based on our proprietary, robust and highly efficient transgenic platform generating fully human VH domain building blocks (Humabody VH) with superior biophysical properties. We can rapidly assemble VH building blocks into an almost limitless number of optimally configured mono- and multi-specific Humabody therapeutics capable of engaging targets in ways that are fundamentally different from IgG. We are therefore able to access novel biology and create products with highly differentiated pharmacological properties
We are building a pipeline of new differentiated medicines, including multi-specific Immuno-Oncology (IO) modulators and Humabody Drug Conjugates (HDCs), through in-house development and strategic partnerships.
Located in Cambridge, UK, we are backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations, Astellas Venture Management, EMBL Ventures, and Takeda.
Humabody® is a registered trademark of Crescendo Biologics Ltd.